Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DTYMK | P23919 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.58 |
| ▸ | TSHR | P16473 | 5/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | RECQL | P46063 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | APEX1 | P27695 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29355161 | 1.00 | DTYMK (0.62) | DTYMKTDP1TSHRALOX15HSD17B10 | |
| SCHEMBL28138122 | 1.00 | DTYMK (0.62) | DTYMKTDP1TSHRALOX15HSD17B10 | |
| Ammonia Solution, Strong SCHEMBL30783526 | 0.98 | DTYMK (0.60) | DTYMKTDP1TSHRALOX15HSD17B10 | |
| Mesalamine SCHEMBL10434139 | 0.92 | ALDH1A1 (0.69) | DTYMKTDP1TSHRALOX15HSD17B10 | |
| 1,6-Hexanediol SCHEMBL8846453 | 0.89 | DTYMK (0.51) | DTYMKTDP1TSHRALOX15HSD17B10 | |
| SCHEMBL30392027 | 0.88 | TDP1 (0.53) | DTYMKTDP1TSHRALOX15HSD17B10 | |
| SCHEMBL8994310 | 0.85 | TDP1 (0.58) | DTYMKTDP1TSHRALOX15HSD17B10 | |
| SCHEMBL616178 | 0.85 | ALOX15 (0.59) | DTYMKTDP1TSHRALOX15HSD17B10 | |
| SCHEMBL1887530 | 0.84 | TSHR (0.56) | DTYMKTDP1TSHRALOX15HSD17B10 | |
| SCHEMBL10773732 | 0.84 | TDP1 (0.56) | DTYMKTDP1TSHRALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 780 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079838-A | Preparation method of 2-nitro-5-thiocyanobenzoic acid | — | 2026-05-26 | — | — | CN | claimed |
| US-20260098058-A1 | COMPOUND - DIAGNOSTIC MARKER FOR OVARIAN CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF OVARIAN CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF OVARIAN CANCER | URTESTE S.A. (PL) | 2026-04-09 | — | — | US | claimed |
| US-20250376711-A1 | COMPOUND-DIAGNOSTIC MARKER FOR UTERINE BODY CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF UTERINE BODY CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF UTERINE BODY CANCER | URTESTE S.A. (PL) | 2025-12-11 | — | — | US | claimed |
| EP-4649167-A2 | COMPOUND - DIAGNOSTIC MARKER FOR BILIARY TRACT CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF BILIARY TRACT CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF BILIARY TRACT CANCER | Urteste S.A. (PL) | 2025-11-19 | — | — | EP | claimed |
| EP-4594335-A1 | COMPOUND - DIAGNOSTIC MARKER FOR OVARIAN CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF OVARIAN CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF OVARIAN CANCER | Urteste S.A. (PL) | 2025-08-06 | — | — | EP | claimed |
| US-20250206777-A1 | COMPOUND - DIAGNOSTIC MARKER FOR INTESTINAL CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF INTESTINAL CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF INTESTINAL CANCER | URTESTE S.A. (PL) | 2025-06-26 | — | — | US | claimed |
| CN-119998307-A | Compound-ovarian cancer diagnostic markers, method for detecting enzymatic activity, method for diagnosing ovarian cancer, kit comprising said compound, use of said compound and method for treating ovarian cancer | 尔特斯特公司 | 2025-05-13 | — | — | CN | claimed |
| EP-4547686-A1 | COMPOUND-DIAGNOSTIC MARKER FOR UTERINE BODY CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF UTERINE BODY CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF UTERINE BODY CANCER | Urteste S.A. (PL) | 2025-05-07 | — | — | EP | claimed |
| EP-4511383-A1 | COMPOUND - DIAGNOSTIC MARKER FOR KIDNEY CANCER, METHOD LOR DETECTING ENZYMATICACTIVITY, METHOD FOR DIAGNOSIS OF KIDNEY CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF KIDNEY CANCER | Urteste S.A. (PL) | 2025-02-26 | — | — | EP | claimed |
| CN-119451973-A | Compound-diagnostic marker for endometrial cancer, method for detecting enzymatic activity, method for diagnosing endometrial cancer, kit containing same, use of same and method for treating endometrial cancer | 尔特斯特公司 | 2025-02-14 | — | — | CN | claimed |
| US-5320945-A | Reacting sample with thrombin and chromogenic peptide substrate, measuring color formed | BOEHRINGER MANNHEIM GMBH (DE) | 1994-06-14 | — | — | US | claimed |
| EP-0513863-A1 | Substrates for determination of enzyme activity and intermediates for synthesis of the substrates as well as process for producing the intermediates | NITTO BOSEKI CO., LTD. (JP) | 1992-11-19 | — | — | EP | claimed |
| US-5115099-A | Modified tripeptides as substrates for determination of enzyme activity | NITTO BOSEKI CO., LTD. (JP) | 1992-05-19 | — | — | US | claimed |
| EP-0216179-B1 | METHOD FOR DETERMINING PROTEASE INHIBITORS | BEHRINGWERKE Aktiengesellschaft (DE) | 1991-08-21 | — | — | EP | claimed |
| EP-0347734-A2 | Substrates for determination of enzyme activity and intermediates for synthesis of the substrates as well as process for producing the intermediates | NITTO BOSEKI CO., LTD. (JP) | 1989-12-27 | — | — | EP | claimed |
| US-4598043-A | Method for quantitatively assaying blood coagulation factor XII in human plasma | PENTAPHARM AG (CH) | 1986-07-01 | — | — | US | claimed |
| US-4480030-A | BLOOD-COAGULATION FACTOR XA | PENTAPHARM A.G. (CH) | 1984-10-30 | — | — | US | claimed |
| US-4440678-A | ARGININES | PENTAPHARM, A.G. (CH) | 1984-04-03 | — | — | US | claimed |
| US-4356277-A | Reaction products of a polyglycidyl ether of a polyphenol and an amino acid and aqueous solubilized products therefrom | PPG INDUSTRIES, INC. (US) | 1982-10-26 | — | — | US | claimed |
| US-4299747-A | LININGS | PPG INDUSTRIES, INC. (US) | 1981-11-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098058-A1 | COMPOUND - DIAGNOSTIC MARKER FOR OVARIAN CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF OVARIAN CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF OVARIAN CANCER | DNPEP, ANPEP, CA9 | DTYMK 1016/4885TDP1 709/4885TSHR 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.